| Prev Close | 48.06 |
| Open | 47.85 |
| Day Low/High | 47.33 / 47.88 |
| 52 Wk Low/High | 36.81 / 50.24 |
| Volume | 941.58K |
| Avg Volume | 1.95M |
| Exchange | NYSE |
| Shares Outstanding | 2.58B |
| Market Cap | 124.19B |
| EPS | 1.80 |
| P/E Ratio | 25.84 |
| Div & Yield | 1.64 (3.40%) |
Latest News
Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies
Upbeat guidance from Target inspires retail rally.
Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target
Upbeat guidance from Target inspires retail rally.
Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences
Sanofi was also recently engaged in two other deals that it lost out on.
Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing...
Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan
Tech, healthcare slide weighs on rest of markets.
Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly
Healthcare's slide weighs on rest of markets.
Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest
If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.
New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c By More Than 2 Percent In Patients With Screening Levels Greater Than 9 Percent
- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -
In Senior Adults Treated With Basal Insulin, Switching To Sanofi's Toujeo® Halved Hypoglycemia Risk
- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -
Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals
Plus more from the biotechnology world on Wednesday, June 7.
Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports
The magnetic tape cartridges in the company's products will be under review.
Symantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks
The cybersecurity firm deemed it 'highly likely' that a group of hackers working with North Korea was behind the attack.
Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices
The legislation would also force companies to announce planned price hikes.
Regeneron Shares Rise After Reporting Better-Than-Expected Sales
The Tarrytown, N.Y.-based biopharmaceutical firm had first-quarter revenue of $1.32 billion.
Dow Holds Lower After House Passes Health Care Vote, Crude Falls
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
Sarepta Therapeutics May Attract Activist Attention
Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen
Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal
Sarepta CEO Ed Kaye said he's stepping down.
Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares
Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.
Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.
Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round
Jim Cramer is bullish on Wingstop, Sanofi, Micron Technology and Nisource.
Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)
True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.
15 Movie Remakes Coming to the Silver Screen in 2017
Whether you loved the original or not, these sequels are making their way to a theater near you.
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:
